¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"FOL"¿¡ ´ëÇÑ Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
5
ÆäÀÌÁö:
7
ÄÚµå
¿µ¹®
ÇѱÛ
Z09
Follow-up examination after treatment for conditions other than malignant neoplasm
¾Ç¼º½Å»ý¹° ÀÌ¿ÜÀÇ º´Å¿¡ ´ëÇÑ Ä¡·áÈÄ ÃßÈİ˻ç
Z08
Follow-up examination after treatment for malig- nant neoplasm
¾Ç¼º½Å»ý¹°ÀÇ Ä¡·áÈÄ ÃßÈİ˻ç
Z09.4
Follow-up examination after treatment of fracture
°ñÀýÄ¡·áÈÄ ÃßÈİ˻ç
Z08.9
Follow-up examination after unspecified treatment for malignant neoplasm
¾Ç¼º½Å»ý¹°¿¡ ´ëÇÑ »ó¼¼ºÒ¸íÀÇ Ä¡·áÈÄ ÃßÈİ˻ç
Z09.9
Follow-up examination after unspecified treatment for other conditions
±âŸ º´Å¿¡ ´ëÇÑ »ó¼¼ºÒ¸íÀÇ Ä¡·áÈÄ ÃßÈİ˻ç
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
ÄÚµå
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½